ClinicalTrials.gg
TerminatedNCT06276556Updated Jul 16, 2025

Extension Study of ABP-671 in Participants With Gout

A Phase 2/3 interventional study of ABP-671 and Allopurinol in Gout, sponsored by Atom Therapeutics Co., Ltd. Terminated at 54 sites in 5 countries. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Atom Therapeutics Co., Ltd · Phase 2/3, Interventional, and Treatment

Why this study was terminated
For business consideration, a new long-term safety study will be conducted in the next new pivotal studies.

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Enrollment
89th of 149
43 · median 74
Started
2024
with 7 others
Phase 2/3
3 of 164
1 open now
Registered
148th of 164
by date
Lead sponsor
5 of 164
Atom Therapeutics Co., Ltd

Among the 164 studies in Gout with a site in United States, this one is the 89th largest by enrollment of the 149 interventional ones that give a count, is one of 8 that started in 2024, is one of 3 in phase 2/3, and was the 148th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).

03

Conditions studied

  • Gout

Browse trials for

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have completed the double-blind Treatment Period in Study ABP-671-301 (Part 1 or Part 2) and are actively receiving and tolerating the study drug up to the Week 28 visit in Study ABP-671-301

Exclusion criteria

Exclusion Criteria:

  • Has a new medical or psychological condition that, in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the participant, interfere with the participant's ability to comply with the protocol requirements to complete the Extension Study, or potentially compromise the results or interpretation of the Extension Study.
  • Is planning to become pregnant or breastfeed during the study or within ≤30 days after the last dose of the study drug.
  • Is intolerant or unwilling to take colchicine or naproxen.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    ABP-671

    Drug: ABP-671

  • Active comparator
    Allopurinol

    Drug: Allopurinol

Interventions

  • Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study. Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study.

  • Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve serum uric acid (sUA) levels <6.0 mg/dL (<0.360 mmol/L)

    Time frame: Week 26

  2. Incidence of treatment-emergent adverse events (Safety and Tolerability)

    Incidence of treatment-emergent adverse events (TEAEs), including AEs of special interest (AESIs), serious AEs (SAEs), and AEs leading to study treatment discontinuation

    Time frame: Week 26

Secondary outcomes

  1. Proportion of participants who achieve sUA levels <5.0 mg/dL (<0.300 mmol/L)

    Time frame: Week 26

07

Study locations

54 sites
  • Alliance for Multispecialty Research
    Tempe, Arizona 85281, United States
  • Tucson Neuroscience Research, LLC
    Tucson, Arizona 85710, United States
  • Anaheim Clinical Trials (Cenexel ACT)
    Anaheim, California 92801, United States
  • Center for Clinical Trials of Sacramento
    Sacramento, California 95823, United States
  • Access Research Institute
    Brooksville, Florida 34613, United States
  • Nature Coast Clinical Reasearch
    Crystal River, Florida 34429, United States
  • JY Research Institute Inc.
    Cutler Bay, Florida 33189, United States
  • Accel Clinical Research Site
    DeLand, Florida 32720, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • A & D Doctor Center
    Miami, Florida 33135, United States
  • Bioclinical Research Alliance
    Miami, Florida 33155, United States
  • Cordova Research Institute
    Miami, Florida 33155, United States
  • Century Research LLC
    Miami, Florida 33173, United States
  • ITB Research
    Miami, Florida 33173, United States
  • Combined Research Orlando Phase I-IV
    Orlando, Florida 32807, United States
  • New Horizons Research
    Palmetto Bay, Florida 33158, United States
  • Advanced Clinical Research of Atlanta
    Atlanta, Georgia 30309, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Alliance for Multispecialty Research, LLC.
    Newton, Kansas 67114, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • AMR
    New Orleans, Louisiana 70119, United States
  • Annapolis Internal Medicine/CCT Research
    Annapolis, Maryland 21401, United States
  • DelRicht Research of Gulfport
    Gulfport, Mississippi 39501, United States
  • Quality Clinical Research, Inc
    Omaha, Nebraska 68114, United States
  • Santa Rosa Medical Center
    Las Vegas, Nevada 89119, United States
  • Inspire Santa Fe Medical Group
    Santa Fe, New Mexico 87505, United States
  • OnSite Clinical Solutions
    Salisbury, North Carolina 28144, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • ClinSearch
    Chattanooga, Tennessee 37421, United States
  • Medical Care/CCT
    Elizabethton, Tennessee 37643, United States
  • PanAmerican Clinical Research, LLC
    Brownsville, Texas 78520, United States
  • Quality Research Inc.
    San Antonio, Texas 78209, United States
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales 2148, Australia
  • Emeritus Research Sydney
    Botany, New South Wales 2019, Australia
  • Paratus Clinical Research Central Coast
    Kanwal, New South Wales 2259, Australia
  • A R Houston Medical Pty Ltd
    Kippa-Ring, Queensland 4021, Australia
  • Emeritus Research Melbourne
    Camberwell, Victoria 3124, Australia
  • Austin Health - Repatriation Hospital
    Heidelberg, Victoria 3084, Australia
  • New Hospitals
    Tbilisi, 0114, Georgia
  • Evex Hospitals Caraps Medline
    Tbilisi, 0159, Georgia
  • Aversi Clini
    Tbilisi, 0160, Georgia
  • The First Medical Center
    Tbilisi, 0180, Georgia
  • Academician Vakhtang Bochorishvili Clinic
    Tbilisi, 0186, Georgia
  • Innova
    Tbilisi, 0186, Georgia
  • Clinical Research Center (CRC)
    Guatemala City, 01010, Guatemala
  • Clínica Médica Especializada en Medicina Interna y Reumatología (CREER)
    Guatemala City, 01010, Guatemala
  • Clínica Médica Especializada en Medicina Interna y Reumatología
    Guatemala City, 01010, Guatemala
  • Clínica Médica Especializada en Medicina Interna
    Guatemala City, 01010, Guatemala
  • Buddhist Dalin Tzu Chi General Hospital
    Chiayi City, 62247, Taiwan
  • Chang Gung Memorial Hospital CGMH
    Kaohsiung City, 833, Taiwan
  • Chung Shan Medical Univ. Hospital
    Taichung, 402367, Taiwan
  • Cheng-Shin General Hospital
    Taipei, 112401, Taiwan
  • Chang Gung Memorial Hospital LinKou
    Taoyuan, 333423, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Sep 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Feb 26, 2024
StartActual
Apr 22, 2024
Primary completionActual
Sep 5, 2024
CompletionActual
Sep 5, 2024
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06276556
Lead sponsor
Atom Therapeutics Co., Ltd
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Apr 22, 2024
Primary completion
Sep 5, 2024
Completion
Sep 5, 2024
Last update
Jul 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABP-671

Start the discussion